CRO start­up Vial scores $67M Se­ries B led by Gen­er­al Cat­a­lyst

Vial, a CRO spe­cial­iz­ing in of­fer­ing clin­i­cal tri­al ser­vices to biotech com­pa­nies, raised $67 mil­lion in a new round of fund­ing, bring­ing its to­tal mon­ey raised to $100 mil­lion.

The San Fran­cis­co-based com­pa­ny’s Se­ries B round was led by Gen­er­al Cat­a­lyst and sup­port­ed oth­ers such as By­ers Cap­i­tal and Box­Group.

Vial co-founder and CEO Si­mon Burns said the com­pa­ny will use the fund­ing to ex­pand its clin­i­cal op­er­a­tions and strat­e­gy teams in the US and across the Eu­ro­pean Union and Asia-Pa­cif­ic in or­der to sup­port its clients glob­al­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA